Early transconjunctival needling revision with 5-fluorouracil versus medical treatment in encapsulated blebs: a 12-month prospective study
Carregando...
Citações na Scopus
10
Tipo de produção
article
Data de publicação
2013
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CLINICS, v.68, n.10, p.1376-1379, 2013
Resumo
OBJECTIVE: To compare the efficacy of transconjunctival needling revision with 5-fluorouracil versus medical treatment in glaucomatous eyes with uncontrolled intraocular pressure due to encapsulated bleb after trabeculectomy. METHODS: Prospective, randomized, interventional study. A total of 40 eyes in 39 patients with elevated intraocular pressure and encapsulated blebs diagnosed at a maximum five months after primary trabeculectomy with mitomycin C were included. The eyes were randomized to either transconjunctival needling revision with 5-fluorouracil or medical treatment (hypotensive eyedrops). A maximum of two transconjunctival needling revisions per patient was allowed in the needling arm. All patients underwent follow-up for 12 months. Successful treatment was defined as an intraocular pressure <= 18 mmHg and a 20% reduction from baseline at the final follow-up. Clinicaltrial.gov: NCT01887223. RESULTS: Mean intraocular pressure at the final 12-month follow-up was lower in the transconjunctival needling revision group compared to the medical treatment group. Similar numbers of eyes reached the criteria for treatment success in both the transconjunctival needling revision group and the medical treatment group. CONCLUSIONS: Despite similar success rates in eyes randomized to transconjunctival needling revision with 5-fluorouracil compared to eyes receiving medical treatment, there was a significantly lower mean intraocular pressure at 12 months after transconjunctival needling revision.
Palavras-chave
Needling, Medical Treatment, Glaucoma, Encapsulated bleb, Revision, 5-Fluorouracil
Referências
- ADDICKS EM, 1983, ARCH OPHTHALMOL-CHIC, V101, P795
- Allen LE, 1998, EYE, V12, P119
- Anand N, 2009, J GLAUCOMA, V18, P513, DOI 10.1097/IJG.0b013e3181911271
- Broadway DC, 2004, OPHTHALMOLOGY, V111, P665, DOI 10.1016/j.ophtha.2003.07.009
- CAMPAGNA JA, 1995, OPHTHALMIC SURG LAS, V26, P57
- Costa VP, 1997, OPHTHALMOLOGY, V104, P1215
- Fagerli M, 2003, ACTA OPHTHALMOL SCAN, V81, P577, DOI 10.1046/j.1600-0420.2003.00126.x
- Greenfield DS, 1996, AM J OPHTHALMOL, V122, P195
- Gutierrez-Ortiz C, 2006, J GLAUCOMA, V15, P98, DOI 10.1097/00061198-200604000-00004
- HODGE W, 1992, CAN J OPHTHALMOL, V27, P233
- Iwach AG, 2003, OPHTHALMOLOGY, V110, P734, DOI 10.1016/S0161-6420(02)01978-4
- Kapasi MS, 2009, J GLAUCOMA, V18, P144, DOI 10.1097/IJG.0b013e318170a71c
- Kapetansky F M, 1999, Semin Ophthalmol, V14, P144, DOI 10.3109/08820539909061467
- King AJ, 2007, BRIT J OPHTHALMOL, V91, P873, DOI 10.1136/bjo.2006.109835
- Maestrini HA, 2011, OPHTHALMOLOGY, V118, P755, DOI 10.1016/j.ophtha.2010.08.020
- Maestrini HA, 2011, ARQ BRAS OFTALMOL, V74, P134, DOI 10.1590/S0004-27492011000200015
- Mathur R, 2002, EYE, V16, P667, DOI 10.1038/sj.eye.6700137
- Paris G, 2004, CLIN EXP OPHTHALMOL, V32, P378, DOI 10.1111/j.1442-9071.2004.00841.x
- PEDERSON JE, 1985, OPHTHALMOLOGY, V92, P955
- Perucho-Martínez S, 2006, Arch Soc Esp Oftalmol, V81, P517
- RICHTER CU, 1988, OPHTHALMOLOGY, V95, P1163
- Rotchford AP, 2008, OPHTHALMOLOGY, V115, P1148, DOI 10.1016/j.ophtha.2007.10.023
- Schwartz AL, 1999, AM J OPHTHALMOL, V127, P8, DOI 10.1016/S0002-9394(98)00290-6
- SCOTT DR, 1988, OPHTHALMOLOGY, V95, P1169
- SHERWOOD MB, 1987, ARCH OPHTHALMOL-CHIC, V105, P1517
- Shetty RK, 2005, J GLAUCOMA, V14, P52, DOI 10.1097/01.ijg.0000146364.90506.7c
- Shin DH, 2001, AM J OPHTHALMOL, V132, P875, DOI 10.1016/S0002-9394(01)01232-6
- SHINGLETON BJ, 1990, OPHTHALMOLOGY, V97, P63
- SKUTA GL, 1987, SURV OPHTHALMOL, V32, P149, DOI 10.1016/0039-6257(87)90091-9